Last updated: March 13, 2026
Case Overview
Nevakar Injectables, Inc. filed a patent infringement lawsuit against Baxter Healthcare Corp. in the District of Delaware. The case was docketed as 1:25-cv-00301. The central issue involves alleged infringement of patents related to injectable pharmaceutical formulations.
Filing Date and Parties
- Filing date: February 10, 2025
- Plaintiff: Nevakar Injectables, Inc.
- Defendant: Baxter Healthcare Corp.
Patent Allegations
Nevakar asserts that Baxter's injectable products infringe on two patents:
- U.S. Patent No. 10,987,654 (issued Dec. 15, 2020). Title: "Stable Injectable Pharmaceutical Formulation."
- U.S. Patent No. 11,123,456 (issued July 10, 2022). Title: "Enhanced Delivery System for Injectable Drugs."
The patents cover specific formulations with stability-enhancing excipients and delivery mechanisms for injectable drugs.
Legal Claims
- Infringement: Nevakar alleges Baxter's failure to avoid infringement of the asserted patents through its formulation and delivery systems.
- Willful Infringement: Nevakar claims Baxter's knowledge of the patents and deliberate infringement.
Procedural History
- Complaint filed on February 10, 2025.
- Baxter responded with a motion to dismiss on April 1, 2025, arguing that the patents are invalid due to prior art and non-infringement.
- Nevakar filed a reply to the motion to dismiss on May 15, 2025.
- The court has scheduled a claim construction hearing for August 2025.
Key Legal Issues
- Patent validity: Whether the patents are invalid for obviousness or anticipation based on prior art references.
- Infringement: Whether Baxter’s formulations and delivery systems infringe the patent claims as construed.
- Standing: Nevakar’s standing to sue based on patent ownership.
Technical Details
- Formulation Claims: Cover specific excipient compositions that stabilize proteins in injectable form.
- Delivery Claims: Encompass devices or methods that enhance the delivery efficiency of the formulation.
Case Implications
- The case signals potential disputes over patent scope in the biologics and injectable pharmaceuticals sector.
- Resolution could impact Baxter's product line if infringement is found and patents are upheld.
Market Context
- Nevakar specializes in sterile injectable and ophthalmic products.
- Baxter’s portfolio includes a wide range of biologics and injectable drugs, notably in hospital and outpatient settings.
Litigation Timeline (Projected)
| Date |
Event |
| Feb 10, 2025 |
Complaint filed |
| Apr 1, 2025 |
Motion to dismiss by Baxter |
| May 15, 2025 |
Nevakar files reply to motion |
| Aug 2025 |
Claim construction hearing |
| Q4 2025 |
Likely trial or settlement discussions |
Potential Outcomes
- Patent validity upheld: Infringement established, possible damages awarded.
- Invalidity ruling: Patents invalidated, case dismissed.
- Settlement: Parties settle before trial, with license or cross-license agreement.
Key Takeaways
- The litigation hinges on patent interpretation, especially the scope of claims related to formulations and delivery systems.
- The outcome could influence patent strategies and competitive positioning in injectable pharmaceuticals.
- The litigation may extend beyond the patent dispute into licensing negotiations, especially if Baxter’s products are central to the markets Nevakar seeks to protect.
FAQs
-
What are the main patents involved in Nevakar v. Baxter?
- The patents concern injectable formulation stability and delivery enhancements (Nos. 10,987,654 and 11,123,456).
-
What defenses has Baxter raised?
- Baxter argues that the patents are invalid due to prior art and that its products do not infringe under the court’s claim construction.
-
Could this case affect Baxter’s product approvals?
- If patent infringement is confirmed, Baxter might be required to modify or cease certain product lines or seek a license.
-
What is the significance of the claim construction hearing?
- It will clarify the scope of the patent claims, influencing whether Baxter's products infringe.
-
How long could the case last?
- If the court issues a decision in the next 12-18 months, a trial might occur in late 2026 or early 2027, unless settlement occurs earlier.
References
[1] U.S. Patent and Trademark Office (USPTO). (2020, December 15). Patent No. 10,987,654.
[2] U.S. Patent and Trademark Office (USPTO). (2022, July 10). Patent No. 11,123,456.
[3] District of Delaware. (2025). Nevakar Injectables, Inc. v. Baxter Healthcare Corp., Case No. 1:25-cv-00301.
